Anthera Pharmaceuticals, Inc.
ANTH
$0.00
$0.000.00%
OTC PK
| 03/31/2018 | 12/31/2017 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -2.44% | 25.41% | |||
| Gross Profit | 2.44% | -25.41% | |||
| SG&A Expenses | 118.94% | -11.60% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.54% | 16.94% | |||
| Operating Income | -18.54% | -16.94% | |||
| Income Before Tax | 20.15% | -53.37% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 20.15% | -53.37% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 20.15% | -53.37% | |||
| EBIT | -18.54% | -16.94% | |||
| EBITDA | -17.25% | -17.11% | |||
| EPS Basic | 43.01% | -27.29% | |||
| Normalized Basic EPS | 52.48% | -27.27% | |||
| EPS Diluted | 43.01% | -27.29% | |||
| Normalized Diluted EPS | 52.48% | -27.27% | |||
| Average Basic Shares Outstanding | 68.05% | 20.49% | |||
| Average Diluted Shares Outstanding | 68.05% | 20.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||